Chimeric Therapeutics Ltd (CHM) - Total Assets
Based on the latest financial reports, Chimeric Therapeutics Ltd (CHM) holds total assets worth AU$5.93 Million AUD (≈ $4.20 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Chimeric Therapeutics Ltd (CHM) net asset quality to measure how much of total assets are equity-financed.
Chimeric Therapeutics Ltd - Total Assets Trend (2020–2025)
This chart illustrates how Chimeric Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data. Explore how much of Chimeric Therapeutics Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Chimeric Therapeutics Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Chimeric Therapeutics Ltd's total assets of AU$5.93 Million consist of 48.8% current assets and 51.2% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 26.7% |
| Accounts Receivable | AU$4.55 Million | 21.1% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$11.04 Million | 51.2% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Chimeric Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CHM market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chimeric Therapeutics Ltd's current assets represent 48.8% of total assets in 2025, a decrease from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 26.7% of total assets in 2025, down from 100.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, a decrease from 13826165.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 51.2% of total assets.
Chimeric Therapeutics Ltd Competitors by Total Assets
Key competitors of Chimeric Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
|
Concord Biotech Limited
NSE:CONCORDBIO
|
India | Rs20.23 Billion |
|
Pharming Group NV
AS:PHARM
|
Netherlands | €473.79 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
Australia | AU$255.67 Million |
|
OPTHEA LTD (SP.ADR/8)
F:UKJ2
|
Germany | €145.77 Million |
Chimeric Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.69 | 0.70 | 0.03 |
| Quick Ratio | 0.69 | 0.70 | 0.03 |
| Cash Ratio | 0.34 | 0.50 | 0.01 |
| Working Capital | AU$-2.26 Million | AU$-3.07 Million | AU$-10.65 Million |
Chimeric Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Chimeric Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.48 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | 41.2% |
| Total Assets | AU$21.57 Million |
| Market Capitalization | $2.38 Million USD |
Valuation Analysis
Below Book Valuation: The market values Chimeric Therapeutics Ltd's assets below their book value (0.11x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Chimeric Therapeutics Ltd's assets grew by 41.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Chimeric Therapeutics Ltd (2020–2025)
The table below shows the annual total assets of Chimeric Therapeutics Ltd from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$21.57 Million ≈ $15.26 Million |
+41.24% |
| 2024-06-30 | AU$15.27 Million ≈ $10.81 Million |
-31.74% |
| 2023-06-30 | AU$22.38 Million ≈ $15.83 Million |
-35.85% |
| 2022-06-30 | AU$34.88 Million ≈ $24.68 Million |
-4.45% |
| 2021-06-30 | AU$36.50 Million ≈ $25.83 Million |
+36504760.00% |
| 2020-06-30 | AU$100.00 ≈ $70.76 |
-- |
About Chimeric Therapeutics Ltd
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurre… Read more